Physician profile
Amanda Walden
NPI 1124682349
$1,167.43
in general payments reported to CMS, 2019-2025
26 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2022: $124 · 2023: $439 · 2024: $213 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $359.98 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $91.29 | 2022-2025 | Bexsero, Pediarix, Penmenvy |
| Bayer Healthcare Pharmaceuticals INC. | $83.04 | 2021-2025 | |
| Abbvie INC. | $77.86 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.07 | 2022-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $54.25 | 2021 | |
| Pfizer INC. | $52.44 | 2022-2025 | |
| Cranial Technologies, INC | $39.33 | 2025 | Doc Band |
| Merck Sharp & Dohme LLC | $33.93 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $31.57 | 2021-2022 | |
| Ibsa Pharma INC. | $22.85 | 2024 | Licart, Tirosint |
| Xeris Pharmaceuticals, INC. | $22.39 | 2024 | Keveyis |
| Daiichi Sankyo INC. | $20.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.58 | 2021 | |
| Eisai INC. | $19.55 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.03 | 2022 | |
| Medtronic, INC. | $18.34 | 2024 | Minimed 780g |
| Astellas Pharma US INC | $17.35 | 2025 | Veozah |
| Dexcom, INC. | $16.69 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $16.34 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.30 | 2024 | Ofev |
| Electromed, INC. | $15.96 | 2025 | Smartvest |
| Sumitomo Pharma America, INC. | $15.52 | 2023 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $15.07 | 2024 | |
| Novo Nordisk INC | $14.62 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Walden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.